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Abstract
Persons with peripheral arterial disease (PAD) are at increased risk for all-cause
mortality, cardiovascular mortality, and mortality from coronary artery disease.
Smoking should be stopped and hypertension, dyslipidemia, diabetes mellitus,
and hypothyroidism treated. Statins reduce the incidence of intermittent clau-
dication and improve exercise duration until the onset of intermittent claudi-
cation in persons with PAD and hypercholesterolemia. The serum low-density
lipoprotein cholesterol should be reduced to < 70 mg/dl. Antiplatelet drugs such
as aspirin or clopidogrel, angiotensin-converting enzyme inhibitors, and statins
should be given to persons with PAD. β-Blockers should be given if coronary
artery disease is present. Cilostazol improves exercise time until intermittent
claudication. Exercise rehabilitation programs should be used. Revasculariza-
tion should be performed if indicated.
Key words: peripheral arterial disease, antiplatelet drugs, statins, exercise, revas-
cularization.
Introduction
Peripheral arterial disease (PAD) is chronic arterial occlusive disease of
the lower extremities caused by atherosclerosis. The PAD may cause inter-
mittent claudication which is pain or weakness with walking that is relieved
with rest. The muscle pain or weakness after exercise occurs distal to the
arterial obstruction. Since the superficial femoral and popliteal arteries are
most commonly affected by atherosclerosis, the pain of intermittent clau-
dication is most commonly localized to the calf. Atherosclerotic obstruc-
tion of the distal aorta and its bifurcation into the two iliac arteries may
cause pain in the buttocks, hips, thighs, or the inferior back muscles as
well as the calves.
The Rutherford classification of PAD includes 7 stages [1]. Table I lists
these 7 stages. Only one-half of elderly persons with documented PAD are
symptomatic. Persons with PAD may not walk far or fast enough to induce
muscle ischemic symptoms because of comorbidities such as pulmonary
disease or arthritis, may have atypical symptoms unrecognized as inter-
mittent claudication [2], may fail to mention their symptoms to their physi-
cian, or may have sufficient collateral arterial channels to tolerate their
arterial obstruction. Women with PAD have a higher prevalence of leg pain
on exertion and at rest, poorer functioning, and greater walking impair-
ment from leg symptoms than men with PAD [3]. Poorer leg strength in
women contributes to poorer lower extremity functioning in women with
PAD than in men with PAD [3]. Women with PAD experience faster func-
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Copyright © 2012 Termedia & Banachtional decline than men with PAD [4]. Greater
sedentary hours and slower outdoor walking speed
are associated with faster declines in functioning
and adverse calf muscle changes in PAD [5]. High-
er physical activity levels during daily life are asso-
ciated with less functional decline in persons with
PAD [6].
If the arterial flow to the lower extremities can-
not meet the needs of resting tissue metabolism,
critical lower extremity ischemia occurs with pain
at rest or tissue loss. Critical ischemia causes rest
pain in the toes or foot with progression to ulcera-
tion or gangrene. Chronic arterial insufficiency ulcers
commonly develop at the ankle, heel, or leg. Mum-
mified, dry, black toes or devitalized soft tissue cov-
ered by a crust is gangrene caused by ischemic
infarction. Suppuration often develops with time,
and dry gangrene changes to wet gangrene. 
Physical examination
The vascular physical examination includes the
components described in Table II.
Noninvasive diagnosis
Persons with PAD of the lower extremities have
decreased or absent arterial pulses. Noninvasive
tests used to assess lower extremity arterial blood
flow include measurement of ankle and brachial
artery systolic blood pressures, characterization of
velocity wave form, and duplex ultrasonography.
Measurement of ankle and brachial artery systolic
blood pressures using a Doppler stethoscope and
blood pressure cuffs allows calculation of the ankle-
brachial index (ABI) which is normally 0.9 to 1.2. An
ABI of less than 0.90 is 95% sensitive and 99% spe-
cific for the diagnosis of PAD [8]. The lower the ABI,
the more severe the restriction of arterial blood flow,
and the more serious the ischemia. The ABIs of 0.6
to 0.9 usually correlate with mild to moderate inter-
mittent claudication. The ABIs of 0.4 to 0.6 usually
correlate with severe intermittent claudication. With
ABIs between 0.25 to 0.4, rest pain and tissue loss
are often found. Patients with calcified arteries from
diabetes mellitus or renal failure occasionally have
relatively non-compressible arteries leading to false-
ly elevated ABI values in the normal range. Persons
with an ABI of 1.4 or higher also have an increased
incidence of cardiovascular events [9] and lower
quality of life [10]. 
In addition to measuring arterial pressure in non-
palpable arteries, Doppler ultrasound methods allow
characterization of the flow versus time velocity
waveform. Finding biphasic flow at the groin or
monophasic flow more distally is evidence of arte-
rial obstruction even when ABI measurements are
falsely increased to normal levels because of calci-
fication. 
Duplex ultrasonography combines Doppler fre-
quency measurements with two-dimensional
images of blood vessels. The severity of flow restric-
tion caused by an arterial stenosis can be accurately
assessed by this most comprehensive noninvasive
method [11]. Duplex ultrasonography, computed
tomographic angiography, and magnetic resonance
angiography are useful in assessing the anatomic
location and severity of PAD and in selecting suit-
able candidates for endovascular or surgical revas-
cularization [7].
Treadmill exercise testing with and without pre-
exercise and postexercise ABIs helps differentiate
claudication from pseudoclaudication in patients
with exertional leg symptoms [7]. Treadmill exer-
cise testing may be useful to diagnose PAD with
a normal resting ABI but a reduced postexercise ABI
[7]. Treadmill exercise testing may objectively doc-
ument the magnitude of symptom limitation in
patients with claudication [7]. The postexercise ABI
is a powerful independent predictor of all-cause
mortality and provides additional risk stratification
than the resting ABI [12]. Patients with coronary
artery disease (CAD) scheduled for coronary artery
bypass graft surgery with PAD should have routine
carotid artery duplex ultrasonography to screen for
carotid arterial disease.
Stage 0 if the patient is asymptomatic
Stage 1 if mild intermittent claudication is present 
Stage 2 if moderate intermittent claudication is present
Stage 3 if severe intermittent claudication is present
Stage 4 if ischemic rest pain is present
Stage 5 if the patient has minor tissue loss
Stage 6 if the patient has ulceration or gangrene
Table I. Rutherford classification of peripheral arte-
rial disease [1]
1. Measurement of blood pressure in both arms
2. Palpation of carotid pulses and listening for carotid 
bruits
3. Auscultation of abdomen and flank for bruits
4. Palpation of abdomen and notation of presence 
of aortic pulsation and its maximal diameter
5. Palpation of pulses at the brachial, radial, ulnar, femoral,
popliteal, dorsalis pedis, and posterior tibial sites
6. Auscultation of both femoral arteries for femoral bruits
7. Remove shoes and socks and inspect feet
8. Evaluate color, temperature, and integrity of skin
9. Note presence of distal hair loss, trophic skin changes, 
hypertrophic nails, and ulcerations
Table II. Vascular physical examination (adapted
from [7])
Wilbert S. Aronow
376 Arch Med Sci 2, April / 2012Arch Med Sci 2, April / 2012 377
Peripheral arterial disease of the lower extremities
Prevalence
The prevalence of PAD increases with age. Schroll
and Munck reported that the prevalence of PAD
was 16% in men and 13% in women aged 60 years
[13]. Criqui et al. showed that the prevalence of PAD
was 5.6% in persons aged 38 to 59 years, 15.9% in
persons aged 60 to 69 years old, and 33.8% in per-
sons aged 70 to 82 years old [14]. In the Cardio-
vascular Health Study, PAD was present in 13.9%
of 2,214 men aged ≥ 65 years and in 11.4% of 2,870
women aged ≥ 65 years without cardiovascular dis-
ease [15]. Symptomatic PAD was present in 20% of
467 men, mean age 80 years, and in 13% of 1,444
women, mean age 81 years, living in the commu-
nity and being seen in a geriatrics clinic [16]. In the
Rotterdam Study, PAD was present in 16.9% of
2,589 men aged ≥ 55 years and in 20.5% of 3,861
women aged ≥ 55 years [17]. The prevalence of
symptomatic PAD was 32% in 1,160 men, mean age
80 years, and 26% in 2,464 women, mean age 81
year, living in a nursing home [18]. The prevalence
of symptomatic PAD in persons living in a nursing
home was also 29% in 268 blacks, mean age 81
years, 24% in 71 Hispanics, mean age 81 years, and
23% in 1,310 whites, mean age 82 years [19]. The
prevalence of symptomatic PAD was 26.7% in 386
men, mean age 72 years, and 17.1% in 620 women,
mean age 72 years, living in the community and
being seen in a university general medicine clinic
[20]. The prevalence of PAD in 6, 979 men and
women, mean age 69 years, screened for PAD by
an ABI because they were aged 70 years or older
or because they were aged 50-69 years with a his-
tory of cigarette smoking or diabetes mellitus was
29% [21]. Among these patients with PAD, classic
claudication was present in only 11% [21]. 
Risk factors
Modifiable risk factors that predispose to PAD
include cigarette smoking [13, 16, 20, 22-30], dia-
betes mellitus [13, 16, 20, 22-29, 31], hypertension
[13, 14, 16, 20, 26-29, 32], dyslipidemia [13, 16, 20,
22, 24-29, 31, 33-35], increased plasma homocys-
teine levels [36-39], and hypothyroidism [40]. Obe-
sity was associated with a high ABI [41]. A reduced
glomerular filtration rate [42-44] and microalbu-
minuria [44] are associated with PAD.
Significant independent risk factors for PAD in
467 men, mean age 80 years, and in 1,444 women,
mean age 81 years, living in the community and
seen in an academic geriatrics paractice were age
(odds ratio = 1.05 for each 1-year increase in age in
men and 1.03 for each 1-year increase in age in
women); current cigarette smoking (odds ratio =
2.6 for men and 4.6 for women); systolic or dias-
tolic hypertension (odds ratio = 2.2 for men and 2.8
for women); diabetes mellitus (odds ratio = 6.1 for
men and 3.6 for women); serum high-density
lipoprotein cholesterol (odds ratio = 0.95 for each 
1 mg/dl increase in men and 0.97 for each 1 mg/dl
increase in women); and serum low-density lipopro-
tein (LDL) cholesterol (odds ratio = 1.02 for each 
1 mg/dl increase in men and in women) [16].
In 147 men and women with PAD and 373 men
and women without PAD, mean age 81 years, plas-
ma homocysteine was a significant independent
risk factor for PAD with an odds ratio of 1.13 for each
1 μmol/l increase [39]. In 249 men and women,
mean age 79 years, the prevalence of PAD was sig-
nificantly higher in persons with subclinical
hypothyroidism (14 of 18 persons or 78%) than in
persons with euthyroidism (40 of 231 persons or
17%) [40]. Elevated plasma glucose and white blood
cell count have also been found to increase the risk
of PAD in asymptomatic diabetics [45].
Coexistence of other atherosclerotic disorders
The PAD coexists with other atherosclerotic dis-
orders [14, 23, 35-40]. In a study of 1,886 men and
women, mean age 81 years, 270 of 468 persons
(58%) with PAD had coexistent CAD and 159 of
468 persons (34%) with PAD had prior ischemic
stroke [46]. The CAD was diagnosed as previous-
ly described [47-52]. Ischemic stroke was diag-
nosed as previously described [52-55]. In a study
of 1,802 men and women, mean age 80 years, liv-
ing in the community and seen in an academic
geriatrics practice, 161 of 236 persons (68%) with
PAD had coexistent CAD and 100 of 236 persons
(42%) with PAD had coexistent prior ischemic
stroke [56]. 
In 924 men, mean age 80 years, the prevalence
of PAD was 1.5 times significantly higher in 336 men
with mitral annular calcium than in 588 men with-
out mitral annular calcium (43% vs. 28%) [56]. In
1,881 women, mean age 81 years, the prevalence of
PAD was 1.6 times significantly higher in 985 women
with mitral annular calcium than in 896 women
without mitral annular calcium (31% vs. 19%) [57].
In 989 men, mean age 80 years, the prevalence
of PAD was 1.6 times significantly higher in 141 men
with valvular aortic stenosis than in 848 men with-
out valvular aortic stenosis (48% vs. 30%) [58]. In
1,998 women, mean age 81 years, the prevalence
of PAD was 1.7 times significantly higher in 321
women with valvular aortic stenosis than in 1,677
women without valvular aortic stenosis (39% vs.
23%) [58].
In 279 men and women, mean age 71 years, with
documented PAD and in 218 men and women,
mean age 70 years, without PAD with normal ABIs
undergoing coronary angiography for suspected
CAD, the prevalence of obstructive CAD was sig-
nificantly higher in persons with PAD (98%) than in
persons without PAD (81%) [29]. The prevalence of378 Arch Med Sci 2, April / 2012
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left main CAD was significantly higher in persons
with CAD (18%) than in persons without CAD (< 1%)
[29]. The incidence of 3-vessel or 4-vessel CAD was
significantly higher in persons with PAD (63%) than
in persons without PAD (11%) [29].
In 1,006 men and women, mean age 72 years, if
PAD was present, 63% had coexistent CAD, and
43% had prior ischemic stroke [20]. In 118 patients,
mean age 73 years, with a decreased ABI, the
prevalence of CAD was 75%, whereas in 118 age-
matched and gender-matched patients with a nor-
mal ABI, the prevalence of CAD was 29% [59]. The
prevalence of aortic valve calcium or mitral annu-
lar calcium was also higher in the patients with
a decreased ABI (69%) than in the patients with
a normal ABI (36%) [59]. 
In 273 patients, mean age 71 years, with CAD,
the lower the ABI, the higher the prevalence of 
3-vessel or 4-vessel CAD [60]. Patients with PAD and
CAD have more extensive and calcified coronary
atherosclerosis, constrictive arterial remodeling, and
greater disease progression [61]. Patients with PAD
also have a higher prevalence of left ventricular sys-
tolic dysfunction than patients without PAD [62].
Cardiovascular events and mortality
Persons with PAD are at increased risk for all-
cause mortality, cardiovascular mortality, and car-
diovascular events [9, 24, 63-78]. At 10-year follow-
up of 565 men and women, mean age 66 years,
PAD significantly increased the risk of all-cause mor-
tality (relative risk = 3.1), of mortality from cardio-
vascular disease (relative risk = 5.9), and of mor-
tality from CAD (relative risk = 6.6) [63]. At 4-year
follow-up of 1,492 women, mean age 71 years, an
ABI of 0.9 or less was associated with a relative risk
of 3.1 for all-cause mortality after adjustment for
age, smoking, and other risk factors [64]. At 5.3-
year follow-up of 6, 647 persons living in the com-
munity, an ABI < 1.0 increased cardiovascular events
1.77 times, and an ABI of 1.40 or higher increased
cardiovascular events 1.85 times [9].
In a prospective study of 291 men and women,
mean age 82 years, with PAD, CAD was present in
160 persons (55%) [56]. Silent myocardial ischemia
detected by 24-h ambulatory electrocardiography
was present in 60 of 160 persons (38%) with PAD
and CAD and in 26 of 131 persons (20%) with PAD
and no clinically evident CAD [65]. At 43-month fol-
low-up, new coronary events developed in 54 of
60 persons (90%) with PAD, CAD, and silent
myocardial ischemia and in 59 of 100 persons
(59%) with PAD, CAD, and no silent myocardial
ischemia [65]. New coronary events also developed
in 18 of 26 persons (69%) with PAD, no CAD, and
silent myocardial ischemia and in 34 of 105 per-
sons (32%) with PAD, no CAD, and no silent
myocardial ischemia [65]. 
A pooled analysis of mortality in 8 large ran-
domized percutaneous coronary intervention (PCI)
trials of 19, 867 patients showed that the presence
of PAD was associated with higher rates of post-
PCI death and myocardial infarction [71]. The PAD
was an independent predictor of short-term and of
long-term mortality [71].
At 7.5-year follow-up of persons in the Cardio-
vascular Health study in a propensity-matched
study of community dwelling older adults, matched
hazard ratios for PAD for all-cause mortality, inci-
dent heart failure, and symptomatic PAD were 1.57,
1.32, and 3.92, respectively [74]. In a well-balanced
propensity-matched population of 2689 patients
with advanced chronic systolic heart failure, dur-
ing 4.1 years of follow-up, PAD was significantly
associated with increased mortality and hospital-
ization [77]. 
Dipyridamole thallium scintigraphy also has 
prognostic value in the preoperative assessment of
patients with PAD undergoing vascular surgery [79].
Risk factor modification
Continuing smoking increases the risk of ampu-
tation in patients with intermittent claudication
[80]. Patency in lower extremity bypass grafts is
also worse in smokers than in nonsmokers [81].
Smoking cessation decreases progression of PAD
to critical leg ischemia and reduces the risk of
myocardial infarction and death from vascular caus-
es [82]. Smokers should be referred to a smoking
cessation program (Table III). 
Approaches to smoking cessation include use of
nicotine patches or nicotine polacrilex gum, which
are available over the counter [83]. If this therapy
is unsuccessful, nicotine nasal spray or treatment
with the antidepressant buproprion should be con-
sidered [83, 84]. A nicotine inhaler may also be used
[85]. The dosage and duration of treatment of each
of these pharmacotherapies are discussed in detail
elsewhere [85]. Varenicline may also be used [86].
Concomitant behavioral therapy may also be need-
ed [87]. Repeated physician advice is very impor-
tant in the treatment of smoking addiction. 
Hypertension should be adequately controlled
to reduce cardiovascular mortality and morbidity in
persons with PAD [32, 88-90] (Table III). The blood
pressure should be reduced to < 140/90 mm Hg
[32]. In the Heart Outcomes Prevention Evaluation
(HOPE) Study, 1715 persons had symptomatic PAD,
and 2118 persons had asymptomatic PAD with an
ABI less than 0.9 [89]. In the HOPE Study, compared
with placebo, ramipril 10 mg daily significantly
reduced cardiovascular events by 25% in persons
with symptomatic PAD [89]. In this study, ramipril
reduced the absolute incidence of cardiovascular
events by 5.9% in persons with asymptomatic PAD
and by 2.3% in persons with a normal ABI [89]. InArch Med Sci 2, April / 2012 379
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the HOPE Study, the antihypertensive properties of
ramipril did not completely account for the observed
risk reduction [89]. 
Among persons with PAD in the Appropriate
Blood Pressure Control in Diabetes trial, the inci-
dence of cardiovascular events in persons treated
with antihypertensive drug therapy with enalapril
or nisoldipine was 13.6% if the mean blood pres-
sure was reduced to 128/75 mm Hg vs. 38.7% if 
the mean blood pressure was reduced to 137/81
mm Hg [90].
Elderly persons with diabetes mellitus and PAD
and no CAD have a 1.5 times higher incidence of
new coronary events than elderly nondiabetics with
PAD and prior MI [91]. The higher the hemoglobin
A1c levels in patients with diabetes mellitus and
PAD, the higher the prevalence of severe PAD [92].
Diabetes mellitus should be treated with the hemo-
globin A1c level decreased to less than 7.0% to
decrease the incidence of myocardial infarction [93].
Some guidelines recommend lowering the blood
pressure in diabetics to < 130/80 mm Hg based on
expert medical opinion [94]. Elderly diabetics with
PAD should also be treated with statins [95] and
the serum low-density lipoprotein (LDL) cholesterol
reduced to < 70 mg/dl [96]. 
Treatment of dyslipidemia with statins has been
documented to reduce the incidence of mortality,
cardiovascular events, and stroke in persons with
PAD with and without CAD [34, 35, 96-104]. 
At 5-year follow-up of 4,444 men and women with
CAD and hypercholesterolemia in the Scandinavian
Simvastatin Survival Study, compared with place-
bo, simvastatin significantly decreased the inci-
dence of intermittent claudication by 38% [97]. 
In a study of 264 men and 396 women, mean age
80 years, with symptomatic PAD and a serum LDL
cholesterol of 125 mg/dl or higher, 318 of 660 per-
sons (48%) were treated with a statin and 342 of
660 persons (52%) with no lipid-lowering drug [102].
At 39-month follow-up, treatment with statins
caused a significant independent reduction in the
incidence of new coronary events of 58%, of 52% in
persons with prior myocardial infarction, and of 59%
in persons with no prior myocardial infarction [102]. 
In the Heart Protection Study, 6748 of the 20536
persons (33%) had PAD [98]. At 5-year follow-up,
treatment with simvastatin 40 mg daily caused
a significant 19% relative reduction and a 6.3%
absolute reduction in major cardiovascular events
independent of age, gender, or serum lipids levels
[98]. These data favor administration of statins to
elderly persons with PAD regardless of serum lipids
levels. The Heart Protection Study also reported that
simvastatin reduced in patients with PAD the rate
of first major vascular events by about one-quar-
ter and that of peripheral vascular events by about
one-sixth, with large absolute benefits seen in
patients with PAD because of their high vascular
risk [104]. 
On the basis of the available data, elderly per-
sons with PAD and hypercholesterolemia should be
treated with statins to reduce cardiovascular mor-
tality and morbidity and progression of PAD [34, 35,
94-104] and to improve exercise time until inter-
mittent claudication [105-107] (Table III). Statins also
reduce perioperative myocardial infarction and mor-
tality [108, 109] and 2-year mortality [109] in
patients undergoing noncardiac vascular surgery.
Although 3 double-blind, randomized, placebo-
controlled studies demonstrated that statins
improve exercise time until intermittent claudica-
tion [105-107], one observational study which was
not placebo-controlled showed in 68 patients with
PAD that despite effective lowering of serum low-
density lipoprotein cholesterol by simvastatin or
ezetimibe, neither tissue perfusion, metabolism,
nor exercise parameters improved, although rest-
ing ABI did [110]. 
1. Refer to smoking cessation program
2. Treatment of hypertension with blood pressure 
reduced to < 140/90 mm Hg 
3. Control diabetes mellitus with the hemoglobin A1c
level reduced to < 7.0%
4. Treat dyslipidemia and reduce serum low-density 
lipoprotein cholesterol to < 70 mg/dl
5. Antiplatelet drug therapy with aspirin or clopidogrel
6. Treatment with an angiotensin-converting enzyme 
inhibitor
7. Treatment with β-blockers in patients with coronary 
artery disease in the absence of contraindications 
to these drugs
8. Use of statins
9. Treatment with cilostazol in patients with intermittent 
claudication
10. Exercise rehabilitation program
11. Foot care
12. Indications for lower extremity percutaneous 
transluminal angioplasty or bypass surgery are: 
• incapacitating claudication in persons interfering with 
work or lifestyle;
• limb salvage in persons with limb-threatening 
ischemia as manifested by rest pain, nonhealing
ulcers, and/or infection or gangrene; 
• vasculogenic impotence
13. Amputation of lower extremities should be performed 
if tissue loss has progressed beyond the point of sal-
vage, if surgery is too risky, if life expectancy is very
low, or if functional limitations diminish the benefit of
limb salvage
Table III. Management of peripheral arterial disease380 Arch Med Sci 2, April / 2012
Since lipid-lowering therapy is underutilized in
persons with PAD [111, 112], intensive educational
programs are needed to educate physicians to use
lipid-lowering therapy in elderly persons with car-
diovascular disease and dyslipidemia [112-114]. On
the basis of data from the Heart Protection Study,
persons with PAD should be treated with statins
regardless of age, gender, or initial serum lipids 
levels [98]. 
Increased plasma homocysteine level is a risk
factor for PAD [30-33]. Reduction of increased plas-
ma homocysteine levels can be achieved by admin-
istering a combination of folic acid, vitamin B6, and
vitamin B12. However, we do not have double-blind,
randomized, placebo-controlled data showing that
reduction of increased plasma homocysteine levels
will reduce coronary events and slow progression
of PAD in elderly persons with PAD. 
Hypothyroidism is a risk factor for PAD [40]. Eld-
erly persons with clinical or subclinical hypothy-
roidism should be treated with l-thyroxine to
decrease the development of CAD [115] and possi-
bly of PAD [40]. There is no evidence showing that
treatment with l-thyroxine will reduce the devel-
opment of PAD or improve symptoms.
Antiplatelet drugs
Antiplatelet drugs that have been shown to
reduce the incidence of vascular death, nonfatal
myocardial infarction, and nonfatal stroke in per-
sons with PAD are aspirin, ticlopidine and clopido-
grel [116]. Aspirin plus dipyridamole has not been
shown to be more efficacious than aspirin alone in
the treatment of persons with PAD [116]. Oral
platelet glycoprotein IIb/IIIa inhibitors have been
shown to increase mortality in the treatment of per-
sons with CAD and have not been investigated in
the treatment of persons with PAD [117]. Adverse
hematologic effects associated with ticlodipine lim-
it the use of this drug in the treatment of elderly
persons with PAD [118].
Thromboxane A2 induces platelet aggregation and
vasoconstriction. Aspirin decreases the aggregation
of platelets exposed to thrombogenic stimuli by
inhibiting the cyclooxygenase enzyme reaction with-
in the platelet and thereby blocking the conversion
of arachidonic acid to thromboxane A2 [119]. Clopi-
dogrel is a thienopyridine derivative that inhibits
platelet aggregation by inhibiting the binding of
adenosine 5’-diphosphate to its platelet receptor [120]. 
The Antithrombotic Trialists’ Collaboration Group
(ATCG) reported a meta-analysis of 26 randomized
studies of 6,263 persons with intermittent claudi-
cation due to PAD [116]. At follow-up, the incidence
of vascular death, nonfatal myocardial infarction,
and nonfatal stroke was 6.4% in patients random-
ized to antiplatelet drugs vs. 7.9% in the control
group, a significant reduction of 23% caused by
antiplatelet therapy. The reductions are significant
for all subgroups.
The ATCG reported a meta-analysis of 12 ran-
domized studies of 2,497 persons with PAD under-
going peripheral arterial grafting [116]. At follow-
up, the incidence of vascular death, nonfatal
myocardial infarction, and nonfatal stroke was 5.4%
in persons randomized to antiplatelet drugs vs.
6.5% in the control group, a significant reduction of
22% caused by antiplatelet therapy.
The ATCG also reported a meta-analysis of 4 ran-
domized studies of 946 persons with PAD under-
going peripheral angioplasty [116]. At follow-up, the
incidence of vascular death, nonfatal myocardial
infarction, and nonfatal stroke was 2.5% in patients
randomized to antiplatelet drugs vs. 3.6% in the
control group, a significant reduction of 29% caused
by antiplatelet therapy.
If one combines the 42 randomized studies of
9,706 patients with intermittent claudication,
peripheral arterial grafting, or peripheral angioplasty,
the incidence of vascular death, nonfatal myocar-
dial infarction, and nonfatal stroke at follow-up was
significantly reduced 23% by antiplatelet drugs, with
similar benefits among patients with intermittent
claudication, those having peripheral arterial graft-
ing, and those having peripheral angioplasty [116].
These data favor the use of aspirin in men and
women with PAD [116] (Table III). 
However, the Aspirin for Asymptomatic Athero-
sclerosis trial showed in 3,350 persons without clin-
ical cardiovascular disease who had an ABI ≤ 0.95
based on screening that compared to placebo,
aspirin 100 mg daily did not reduce vascular events
[121]. A post hoc analysis of the 3,096 patients with
PAD in the Clopidogrel for High Atherothrombotic
Risk and Ischemic, Management, and Avoidance
(CHARISMA) trial showed that the primary endpoint
of cardiovascular death or nonfatal myocardial
infarction or nonfatal stroke was insignificantly
reduced by 15% from 8.9% in patients treated
aspirin plus placebo to 7.6% in patients treated with
aspirin plus clopidogrel [122]. 
The reduction in high-risk persons of the inci-
dence of vascular death, nonfatal MI, and nonfatal
stroke was 19% in 34 trials using an aspirin dose of
500-1500 mg daily, 26% in 19 trials using an aspirin
dose of 160-325 mg daily, 32% in 12 trials using an
aspirin dose of 75-150 mg daily, and 13% in 3 trials
using an aspirin dose of < 75 mg daily [116]. Since
aspirin doses greater than 150 mg daily do not
reduce vascular death, nonfatal myocardial infarc-
tion, and nonfatal stroke more than does a dose of
75 mg to 150 mg daily and cause more gastroin-
testinal bleeding than the lower doses, this author
prefers an aspirin dose of 81 mg daily in treating eld-
erly persons with atherosclerotic vascular disease.
In the Clopidogrel vs. Aspirin in Patients at Risk
for Ischaemic Events (CAPRIE) trial, 5,795 persons
with PAD were randomized to clopidogrel 75 mg
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daily and 5,797 persons with PAD were randomized
to aspirin 325 mg daily [123]. At 1.9-year follow-up,
the annual incidence of vascular death, nonfatal
myocardial infarction, and nonfatal stroke was 3.7%
in persons randomized to clopidogrel vs. 4.9% in
persons randomized to aspirin, a 24% significant
decrease with the use of clopidogrel [123]. 
On the basis of these data, it is reasonable to
conclude that clopidogrel is superior to aspirin in
the management of patients with PAD. However,
clopidogrel is much more expensive than is aspirin.
In a vascular surgery clinic, 501 of 561 persons
(89%) with PAD were treated with aspirin or clopi-
dogrel [124]. 
Oral anticoagulants
In the Dutch Bypass Oral Anticoagulants or
Aspirin Study, 2690 persons were randomized after
infrainguinal bypass surgery to aspirin 80 mg dai-
ly or to oral anticoagulation with phenprocoumon
or acenocoumarol to maintain an INR of 3.0-4.5
[120]. At 21-month follow-up, there was no signifi-
cant difference between the two treatments in the
primary outcome of infrainguinal graft occlusion
[125]. There was no significant difference between
the two treatments in the secondary outcomes of
myocardial infarction, stroke, amputation, or vas-
cular death [125]. However, persons treated with
oral anticoagulant therapy had 1.96 times more
major bleeding episodes than persons treated with
oral aspirin [125]. The American College of Cardiol-
ogy (ACC)/American Heart Association (AHA) guide-
lines state that oral anticoagulant therapy with war-
farin should not be given to decrease the risk of
adverse cardiovascular ischemic events in persons
with atherosclerotic lower extremity PAD [7].
Angiotensin-converting enzyme inhibitors
Data from the HOPE Study showed that ramipril
10 mg daily significantly decreased cardiovascu-
lar events in persons with symptomatic PAD and
in persons with asymptomatic PAD [89]. Angio  -
tensin-converting enzyme inhibitors as well as
statins also have many pleotropic effects to
account for their vascular protective properties
beyond their primary mode of action including
inhibition of cellular proliferation, restoration of
endothelial activity, inhibition of platelet reacti  -
vity, and an antioxidant potential [126]. The
ACC/AHA guidelines recommend treating persons
with PAD with angiotensin-converting enzyme
inhibitors unless there are contraindications to the
use of these drugs to reduce cardiovascular mor-
tality and morbidity [127] (Table III).
β-Blockers
Persons with PAD are at increased risk for devel-
oping new coronary events [24, 63-78]. Many physi-
cians have been reluctant to use β-blockers in per-
sons with PAD because of concerns that β-blockers
will aggravate intermittent claudication. However,
a meta-analysis of 11 randomized controlled studies
found that β-blockers do not adversely effect walk-
ing capacity or the symptoms of intermittent clau-
dication in persons with mild-to-moderate PAD [128]. 
An observational study was performed in 575
men and women, mean age 80 years, with symp-
tomatic PAD and prior myocardial infarction [129].
Of the 575 persons, 85 (15%) had contraindications
to the use of β-blockers. Of the 490 persons 
without contraindications to the use of β-blockers, 
257 persons (52%) were treated with β-blockers.
Adverse effects causing cessation of β-blockers
occurred in 31 of the 257 persons (12%). At 
32-month follow-up, use of β-lockers caused a 53%
significant independent reduction in the incidence
of new coronary events in elderly persons with PAD
and prior myocardial infarction [129]. In a vascular
surgery clinic, 301 of 364 persons (83%) with PAD
and CAD were treated with β-blockers [124]. 
β-Blockers should be used to treat CAD in patients
with PAD in the absence of contraindications to
these drugs (Table III).
Statins
On the basis of data from the Heart Protection
Study, persons with PAD should be treated with
statins regardless of age, gender, or initial serum
lipids levels [98] (Table III). Three double-blind, ran-
domized, placebo-controlled studies have also
demonstrated that statins improve walking per-
formance in persons with PAD [105-107]. 
In a study of 69 persons, mean age 75 years,
with intermittent claudication, a mean ABI of 0.63,
and a serum LDL cholesterol of 125 mg/dl or high-
er, 3 of 34 persons (9%) treated with simvastatin
and 6 of 35 persons (17%) treated with placebo died
before the 1-year study was completed [105]. Com-
pared with placebo, simvastatin significantly
increased treadmill exercise time until the onset of
intermittent claudication by 24% at 6 months and
by 42% at 1 year after therapy [105].
In a study of 354 persons, mean age 68 years,
with intermittent claudication and hypercholes-
terolemia, at 1-year follow-up, compared with place-
bo, atorvastatin 80 mg daily significantly improved
pain-free treadmill walking distance by 40% and
significantly improved community-based physical
activity [106]. In a study of 86 persons, mean age
67 years, with intermittent claudication and hyper-
cholesterolemia, at 6-month follow-up, compared
with placebo, simvastatin 40 mg daily significantly
improved pain-free walking distance and total walk-
ing distance on a treadmill, significantly improved
the mean ABI at rest and after exercise, and sig-
nificantly improved symptoms of claudication [107]. 382 Arch Med Sci 2, April / 2012
Statin use is also associated with superior leg
functioning independent of cholesterol levels and
other potential confounders [130]. The data sug-
gest that non-cholesterol-lowering properties of
statins may favorably influence functioning in per-
sons with and without PAD [130].
Drugs to increase walking distance
Chelation therapy has been documented to be
ineffective in the therapy of PAD [131]. Numerous
drugs have been demonstrated to be ineffective in
improving walking distance in persons with inter-
mittent claudication [132, 133]. Beraprost sodium,
an orally active prostaglandin I2 analogue, was
demonstrated to be no more effective than place-
bo in persons with intermittent claudication [134].
Naftidrofuryl [135] and propionyl levocarnitine [136]
have been reported to improve exercise walking dis-
tance in persons with intermittent claudication but
have not been approved for use in the United
States [132]. 
Two drugs, pentoxifylline and cilostazol, have
been approved by the United States Food and Drug
Administration for symptomatic treatment of inter-
mittent claudication. However, many studies have
found no consistent improvement with pentoxi-
fylline in patients with intermittent claudication in
comparison with placebo [137-139]. In a vascular
surgery clinic, 301 of 301 persons (100%) with inter-
mittent claudication were treated with cilostazol or
pentoxifylline [124]. 
Cilostazol inhibits phosphodiesterase type 3,
increasing intracellular concentration of cyclic
adenosine monophosphate. Cilostazol suppresses
platelet aggregation and also acts as a direct arte-
rial vasodilator. Cilostazol has been documented in
numerous trials to improve exercise capacity in
patients with intermittent claudication [133, 140-
143], and in a dose of 100 mg twice daily, was
shown to be superior to both placebo and pentox-
ifylline [142]. 
Cilostazol should be given to patients with PAD
to increase walking distance (Table III) but should
not be given to persons with PAD who also have
heart failure. Other contraindications to the use of
cilostazol include a creatinine clearance < 25 ml/
min, a known predisposition for bleeding, or 
coadministration of CYP3A4 or CYP2C19 inhibitors
such as cimetidine, diltiazem, erythromycin, keto-
conazole, lansoprazole, omeprazole, and HIV-1 pro-
tease inhibitors. 
Exercise rehabilitation programs
Exercise rehabilitation programs have been
shown to increase walking distance in persons with
intermittent claudication through improvements in
peripheral circulation, walking economy, and car-
diopulmonary function [144, 145]. The optimal exer-
cise program for improving claudication pain dis-
tance in persons with PAD uses intermittent walk-
ing to near-maximal pain during a program of at
least 6 months [146]. Strength training is less effec-
tive than treadmill walking [147].The ACC/AHA
guidelines recommend a supervised exercise pro-
gram for patients with intermittent claudication [7]
(Table III). 
Supervised exercise training is recommended for
a minimum of 30-45 min in sessions performed at
least 3 times per week for a minimum of 12 weeks
[7] and preferably for 6 months or longer [146].
Among persons with PAD, self-directed walking
exercise performed at least 3 times weekly is asso-
ciated with significantly less functional decline dur-
ing the subsequent year [148].
Foot care
Persons with PVD must have proper foot care 
[7, 149] (Table III). They must wear properly fitted
shoes. Careless nail clipping or injury from walking
barefoot must be avoided. Feet should be washed
daily and the skin kept moist with topical emollients
to prevent cracks and fissures, which may have por-
tals for bacterial infection. Fungal infection of the
feet must be treated. Socks should be wool or oth-
er thick fabrics, and padding or shoe inserts may
be used to prevent pressure sores. When a wound
of the foot develops, specialized foot gear, includ-
ing casts, boots, and ankle foot arthoses may be
helpful in unweighting the affected area [149].
Lower extremity angioplasty and bypass surgery
Indications for lower extremity percutaneous
transluminal angioplasty or bypass surgery are: 
1) incapacitating claudication in persons interfering
with work or lifestyle; 2) limb salvage in persons
with limb-threatening ischemia as manifested by
rest pain, nonhealing ulcers, and/or infection or
gangrene; and 3) vasculogenic impotence [150]. Per-
cutaneous transluminal angioplasty can be per-
formed if there is a skilled vascular interventional-
ist and the arterial disease is localized to a vessel
segment less than 10 cm in length [141]. Compared
to percutaneous transluminal angioplasty alone,
stenting improves 3-year patency by 26%) [151].
Patients treated with drug-eluting stents should be
treated with aspirin plus clopidogrel for at least 
1 year. After infrainguinal bypass surgery, oral anti-
coagulant therapy is preferable in persons with
venous grafts, whereas aspirin is preferable in per-
sons with nonvenous grafts [152]. 
Percutaneous balloon angioplasty and/or stent-
ing is indicated for short-segment stenoses, where-
as multisegment disease and occlusions are most
effectively treated with surgical revascularization
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[153]. Revascularization of PAD is discussed exten-
sively elsewhere [7, 149]. In patients presenting with
severe limb ischemia caused by infra-inguinal dis-
ease and who are suitable for either surgery or
angioplasty, by-pass surgery and balloon-angio-
plasty are associated with similar outcomes in
terms of amputation-free survival [154]. Patients
with intermittent claudication should be considered
for revascularization to improve symptoms only in
the absence of other disease that would limit exer-
cise improvement such as angina pectoris, heart
failure, chronic pulmonary disease, or orthopedic
limitations [7].
Amputation
Nonrandomized studies have shown that both
immediate and long-term survival are higher in
patients having revascularization rather than ampu-
tation for limb-threatening ischemia [155, 156].
However, amputation of lower extremities should
be performed if tissue loss has progressed beyond
the point of salvage, if surgery is too risky, if life
expectancy is very low, or if functional limitations
diminish the benefit of limb salvage [149].
The European Society of Cardiology guidelines
on the diagnosis and treatment of PAD were recent-
ly published online in the August 26, 2011 issue of
the European Heart Journal [157]. I concur with
these excellent guidelines and recommend that all
physicians should read them. 
Future research needs to be performed investi-
gating the role of inflammation in the pathogene-
sis of PAD. Additional therapies are needed to
improve the quality of life and outcomes in patients
with PAD. Further research is needed in angiogen-
esis gene therapy and stem cell or progenitor cell
therapy in patients with critical limb ischemia.
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